The first tissue-agnostic/site-agnostic medication, pembrolizumab is effective for treating melanoma, NSCLC, recurrent or metastatic cervical cancer, metastatic SCLC, endometrial carcinoma, TMB-H solid tumors, MSI-H or dMMR CRC, triple-negative breast cancer expressing PD-L1 and other types of cancer (Arias-Pinilla and Modjtahedi 2021). The gene discussed is CD274; the disease is triple-negative breast carcinoma.